C. Llacer-Moscardo

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · The Lancet Oncology · 2014 · 446 citations

Medicine, Oncology, Radiation Oncology +15

Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure

M. de Méric de Bellefon, C. Lemanski, Florence Castan et al. · Radiotherapy and Oncology · 2019 · 37 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · Journal of Clinical Oncology · 2012 · 18 citations

Medicine, Oncology, Radiation Oncology +16

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · Journal of Clinical Oncology · 2012 · 15 citations

Medicine, Oncology, Radiation Oncology +16

Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results

C. Llacer-Moscardo, O. Riou, D. Azria et al. · Reports of Practical Oncology & Radiotherapy · 2016 · 13 citations · Full text

Medicine, Oncology, Radiation Oncology +16